多发性骨髓瘤患者骨髓活检中 LMP1 的表达可带来生存优势。

LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage.

机构信息

a Centre for Regenerative Medicine and Stem Cell Research, Aga Khan University , Karachi , Pakistan.

b Department of Pathology and Laboratory Medicine , Aga Khan University , Karachi , Pakistan.

出版信息

Leuk Lymphoma. 2019 Aug;60(8):1991-2001. doi: 10.1080/10428194.2018.1563697. Epub 2019 Mar 26.

DOI:10.1080/10428194.2018.1563697

PMID:30912465

Abstract

Multiple myeloma (MM) is a heterogeneous disease of the bone marrow (BM). Its association with Epstein-Barr virus (EBV) remains enigmatic. Aim of our study was to determine expression of latent membrane protein 1 (LMP1), aldehyde dehydrogenase 1 (ALDH1), CD117 and their association with 5-year survival in MM patients. Seven percent of cases expressed LMP1 in MM cells with no association with survival. Whereas, LMP1 expression in CD138- non-neoplastic cells was observed in 80% of the cases, conferring a survival advantage of 1.75 years (mean 3.75 ± 0.28, 95% CI 3.19-4.3). LMP1 in CD138- non-neoplastic cells was associated with CD117 expression in MM cells. Combinatorial analysis of LMP1 and CD117 stratified patients into good prognostic group LMP1+/CD117- (mean survival 4.16 ± 0.39 years) and a worst prognostic group; LMP1-/CD117+ (mean survival 1.02 ± 0.29 years). Our study showed that LMP1 expression in CD138- non-neoplastic cells of BM in MM patients confers a survival advantage.

摘要

多发性骨髓瘤（MM）是一种骨髓（BM）的异质性疾病。它与 Epstein-Barr 病毒（EBV）的关联仍然是个谜。我们的研究目的是确定潜伏膜蛋白 1（LMP1）、醛脱氢酶 1（ALDH1）、CD117 的表达及其与 MM 患者 5 年生存率的关系。7%的病例 MM 细胞中表达 LMP1，但与生存无关。然而，在 80%的病例中观察到 CD138-非肿瘤细胞中 LMP1 的表达，这使其生存优势延长了 1.75 年（平均 3.75±0.28，95%CI 3.19-4.3）。CD138-非肿瘤细胞中的 LMP1 与 MM 细胞中的 CD117 表达相关。LMP1 和 CD117 的组合分析将患者分层为预后良好的 LMP1+/CD117-组（平均生存 4.16±0.39 年）和预后最差的 LMP1-/CD117+组（平均生存 1.02±0.29 年）。我们的研究表明，MM 患者 BM 中 CD138-非肿瘤细胞中的 LMP1 表达可带来生存优势。